DexCom, Inc.

{
  "main_header": {
    "sid": 1153155,
    "name": "DexCom, Inc.",
    "stock_name": "DexCom, Inc.",
    "full_name": "DexCom, Inc.",
    "name_url": "stocks-analysis/dexcom-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "70.73",
    "chg": -14.95,
    "chgp": "-17.45%",
    "dir": -1,
    "prev_price": "85.68",
    "mcapval": "30,658.31",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US2521311074",
    "curr_date": "Jan 20",
    "curr_time": "",
    "bse_nse_vol": "3.57 M",
    "exc_status": "Active",
    "traded_date": "Jan 20, 2026",
    "traded_date_str": "2026 01 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dexcom-inc-1153155-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is DexCom, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dexcom-inc-overvalued-or-undervalued-3673399",
        "imagepath": "",
        "date": "2025-11-05 11:10:48",
        "description": "As of 31 October 2025, the valuation grade for DexCom, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. has a more attractive P/E ratio of 27.42 and an EV to EBITDA of 20.749, indicating that DexCom may be relatively overvalued against its peer.\n\nDespite the fair valuation, DexCom has underperformed significantly compared to the S&P 500, with a year-to-date return of -21.33% versus the S&P 500's 16.30%. This underperformance over multiple periods suggests that investors may need to reassess their expectations regarding the company's growth prospects...."
      },
      {
        "title": "Is DexCom, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dexcom-inc-overvalued-or-undervalued-3670594",
        "imagepath": "",
        "date": "2025-11-04 11:16:47",
        "description": "As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company is currently fairly valued based on its valuation metrics. Key ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. is fairly valued with a P/E of 27.42, while Edwards Lifesciences Corp. is considered expensive with a P/E of 31.17.\n\nDespite the fair valuation, DexCom has underperformed significantly compared to the S&P 500, with a year-to-date return of -22.30% versus the index's 16.30%. This trend is further reflected in the three-year return of -46.33% compared to the S&P 500's 76.66%, indicating that while the stock may be fairly valued, its recent performance has been disappointing...."
      },
      {
        "title": "DexCom Stock Hits Day Low of $56.45 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dexcom-stock-hits-day-low-of-5645-amid-price-pressure-3667380",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DexComInc_priceRelatedfactors_3667380.png",
        "date": "2025-11-03 17:41:48",
        "description": "DexCom, Inc. faced notable stock volatility on October 31, 2025, with a significant decline. Over the past week and month, the company's performance has weakened, contrasting with the S&P 500. Despite this, DexCom maintains a strong financial profile, including high return on equity and robust sales growth."
      },
      {
        "title": "DexCom, Inc. Hits New 52-Week Low at $56.45 Amid Market Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dexcom-inc-hits-new-52-week-low-at-5645-amid-market-struggles-3667300",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DexComInc_priceRelatedfactors_3667300.png",
        "date": "2025-11-03 17:11:01",
        "description": "DexCom, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company, valued at approximately USD 30.66 billion, has a high P/E ratio and does not offer dividends. Its financial metrics indicate a conservative leverage approach and effective management of shareholder equity."
      },
      {
        "title": "DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dexcoms-valuation-grade-changes-from-expensive-to-fair-amid-price-decline-3667032",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DexComInc_valuationdot_3667032.png",
        "date": "2025-11-03 15:34:50",
        "description": "DexCom, Inc. has experienced a valuation adjustment, with its stock price declining significantly over the past year. The company reports a P/E ratio of 64 and an EV to EBITDA ratio of 39.43, indicating a premium valuation compared to competitors. Its operational efficiency is highlighted by a ROCE of 31.15% and ROE of 23.61%."
      },
      {
        "title": "Is DexCom, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dexcom-inc-overvalued-or-undervalued-3666164",
        "imagepath": "",
        "date": "2025-11-03 11:16:14",
        "description": "As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, peers such as Edwards Lifesciences Corp. have a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a P/E of 27.42 and an EV to EBITDA of 20.75, indicating that DexCom is priced higher than its peers.\n\nDespite the recent adjustment in valuation, DexCom's stock has underperformed significantly against the S&P 500, with a year-to-date return of -25.14% compared to the S&P 500's 16.30%. This stark contrast in returns reinforces the notion that while the company's valuation has improved, it still faces challenges in the market...."
      },
      {
        "title": "Is DexCom, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dexcom-inc-overvalued-or-undervalued-3664292",
        "imagepath": "",
        "date": "2025-11-02 11:09:12",
        "description": "As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. is fairly valued with a P/E of 27.42, while Edwards Lifesciences Corp. is considered expensive with a P/E of 31.17.\n\nDespite the recent grade change, DexCom has underperformed relative to the S&P 500, with a year-to-date return of -25.14% compared to the S&P 500's 16.30%. This significant underperformance may suggest that the market has not fully recognized the fair valuation of the stock...."
      }
    ],
    "total": 27,
    "sid": "1153155",
    "stock_news_url": "https://www.marketsmojo.com/news/dexcom-inc-1153155"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is DexCom, Inc. overvalued or undervalued?

2025-11-05 11:10:48

As of 31 October 2025, the valuation grade for DexCom, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. has a more attractive P/E ratio of 27.42 and an EV to EBITDA of 20.749, indicating that DexCom may be relatively overvalued against its peer. Despite the fair valuation, DexCom has underperformed significantly compared to the S&P 500, with a year-to-date return of -21.33% versus the S&P 500's 16.30%. This underperformance over multiple periods suggests that investors may need to reassess their expectations regarding the company's growth prospects....

Read full news article

Is DexCom, Inc. overvalued or undervalued?

2025-11-04 11:16:47

As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company is currently fairly valued based on its valuation metrics. Key ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. is fairly valued with a P/E of 27.42, while Edwards Lifesciences Corp. is considered expensive with a P/E of 31.17. Despite the fair valuation, DexCom has underperformed significantly compared to the S&P 500, with a year-to-date return of -22.30% versus the index's 16.30%. This trend is further reflected in the three-year return of -46.33% compared to the S&P 500's 76.66%, indicating that while the stock may be fairly valued, its recent performance has been disappointing....

Read full news article

DexCom Stock Hits Day Low of $56.45 Amid Price Pressure

2025-11-03 17:41:48

DexCom, Inc. faced notable stock volatility on October 31, 2025, with a significant decline. Over the past week and month, the company's performance has weakened, contrasting with the S&P 500. Despite this, DexCom maintains a strong financial profile, including high return on equity and robust sales growth.

Read full news article

DexCom, Inc. Hits New 52-Week Low at $56.45 Amid Market Struggles

2025-11-03 17:11:01

DexCom, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company, valued at approximately USD 30.66 billion, has a high P/E ratio and does not offer dividends. Its financial metrics indicate a conservative leverage approach and effective management of shareholder equity.

Read full news article

DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics

2025-11-03 15:34:50

DexCom, Inc. has experienced a valuation adjustment, with its stock price declining significantly over the past year. The company reports a P/E ratio of 64 and an EV to EBITDA ratio of 39.43, indicating a premium valuation compared to competitors. Its operational efficiency is highlighted by a ROCE of 31.15% and ROE of 23.61%.

Read full news article

Is DexCom, Inc. overvalued or undervalued?

2025-11-03 11:16:14

As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, peers such as Edwards Lifesciences Corp. have a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a P/E of 27.42 and an EV to EBITDA of 20.75, indicating that DexCom is priced higher than its peers. Despite the recent adjustment in valuation, DexCom's stock has underperformed significantly against the S&P 500, with a year-to-date return of -25.14% compared to the S&P 500's 16.30%. This stark contrast in returns reinforces the notion that while the company's valuation has improved, it still faces challenges in the market....

Read full news article

Is DexCom, Inc. overvalued or undervalued?

2025-11-02 11:09:12

As of 31 October 2025, the valuation grade for DexCom, Inc. has moved from expensive to fair. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. is fairly valued with a P/E of 27.42, while Edwards Lifesciences Corp. is considered expensive with a P/E of 31.17. Despite the recent grade change, DexCom has underperformed relative to the S&P 500, with a year-to-date return of -25.14% compared to the S&P 500's 16.30%. This significant underperformance may suggest that the market has not fully recognized the fair valuation of the stock....

Read full news article

View All News